The short version of aggregation fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2025-07-31 and is reviewed periodically as new material appears.
Certificate of analysis documents from suppliers typically report purity by chromatographic area, water content, and counter-ion identity. Independent verification is advisable because reported values can be generated under differing conditions. Impurity profiles matter for research use, where aggregates, deamidation products, and residual solvents may influence experimental results. Container, lot, and chain-of-custody records support traceability. Analytical results are method-dependent, so comparisons between laboratories require the same procedure and reference standards.
Lyophilized peptide material is typically stored at or below -20 °C, with -80 °C used for longer-term archives. Vials should remain sealed and desiccated because moisture promotes aggregation and hydrolysis. Repeated freeze-thaw cycles are avoided since they can alter peptide conformation and reduce recovery. Once reconstituted, solutions are generally kept at 2-8 °C and used within a defined window. Stability beyond those windows depends on buffer composition and concentration, and exact limits are product-specific rather than universal.
The primary target is the GLP-1 receptor, a class B G protein-coupled receptor expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises intracellular cyclic AMP, which potentiates glucose-dependent insulin secretion and lowers glucagon release when blood glucose is elevated. Signalling in the hypothalamus and brainstem is associated with reduced appetite and slower gastric emptying. Because the insulinotropic effect depends on prevailing glucose levels, the hypoglycaemic risk of the peptide alone is described as low in most study settings. The relative contribution of peripheral and central actions remains an active research question.
Large randomised trials in adults with type 2 diabetes and in adults with obesity have reported reductions in body weight and improvements in several cardiovascular risk markers. One outcome trial found a lower incidence of major adverse cardiovascular events in participants with diabetes and established cardiovascular disease. Gastrointestinal effects such as nausea and vomiting are the most frequently reported adverse events and often diminish over time. Changes in lean body mass during weight loss are an area of ongoing investigation. Effects in adolescents and in pregnancy are less well characterised, and current labelling advises against use during pregnancy.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released after nutrient intake. The molecule contains 31 amino acid residues and differs from the native sequence at several positions. A non-natural residue at position eight resists the enzyme that normally truncates the hormone, while a lysine-linked fatty diacid side chain promotes binding to serum albumin. These two modifications extend the circulating half-life from minutes to roughly one week. The peptide is produced by solid-phase synthesis followed by selective acylation, and its identity and purity are confirmed by spectrometric and chromatographic techniques.
| Property | Value | Notes |
|---|---|---|
| Storage temperature | -20 °C or below | Lyophilized powder; -80 °C for long-term archival |
| Post-reconstitution storage | 2-8 °C | Refrigerated; avoid repeated freeze-thaw |
| Routine purity method | Reversed-phase HPLC | Separates peptide from related impurities |
| Identity confirmation | Mass spectrometry | Confirms molecular mass and detects truncation |
| Water solubility | Freely soluble | Depends on salt form and buffer composition |
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Semaglutide 是一种经结构修饰的胰高血糖素样肽-1 类似物，其主链与内源性 GLP-1(7-36) 约有百分之九十四的序列一致性。第 8 位丙氨酸被 α-氨基异丁酸取代，使二肽基肽酶-4 无法识别原有切割位点。第 34 位赖氨酸换为精氨酸，进一步降低酶解速率。第 26 位赖氨酸经间隔基连接一条含十八个碳的二酸脂肪链，该侧链赋予分子与血浆白蛋白结合的能力。
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
== Honors and awards == Alfred Burger Award in Medicinal Chemistry, American Chemical Society, 1981 Thomas Alva Edison Patent Award, Research and Development Council, New Jersey, 1983 Ciba Award for Hypertension Research, American Heart Association, Council on High Blood Pressure Research, 1983 Chairman's Edward Robinson Squibb Award, E. R. Squibb & Sons, Inc., 1986 Award for Contributions to Medical Science, Pharmaceutical Manufacturers Association and National Health Council, 1988 Inventor of the Year Award, New Jersey Inventors Congress, 1988 Perkin Medal, Society of Chemical Industry, American Section, 1991 Warren Alpert Foundation Prize, Harvard Medical School, 1991 Award for Creative Invention, American Chemical Society, 1992 Herman Bloch Award for Scientific Excellence in Industry, University of Chicago, 1992 Lasker-DeBakey Clinical Medical Research Award, 1999
==== Conditional requirements ==== In addition, cysteine, tyrosine, and arginine are considered semiessential amino acids, and taurine a semi-essential aminosulfonic acid in children. Some amino acids are conditionally essential for certain ages or medical conditions. Essential amino acids may also vary from species to species. The metabolic pathways that synthesize these monomers are not fully developed.
== Pathophysiology == As of 2016, the pathophysiology of tendinopathy was poorly understood. While inflammation plays a role, the relationships among changes to the structure of tissue, the function of tendons, and pain are not understood. Several models are proposed, none of which have been fully validated or falsified. Molecular mechanisms involved in inflammation include release of inflammatory cytokines such as IL-1β which reduce the expression of type I collagen mRNA in human tenocytes and cause extracellular matrix degradation in the tendon. A 2020 review noted that while various inflammatory markers were present in two thirds of the reviewed articles, data heterogeneity and lack of comparable studies prevented any conclusion about a common pathophysiology. Multifactorial theories include tensile overload, tenocyte-related collagen synthesis disruption, load-induced ischemia, neural sprouting, thermal damage, and adaptive compressive responses. The intratendinous sliding motion of fascicles and shear force at interfaces of fascicles could predispose tendons to rupture. The most commonly accepted cause is an overuse syndrome in combination with factors leading to what may be seen as a progressive interference or the failing of the innate healing response. Tendinopathy involves apoptosis, matrix disorganization and neovascularization. Classic characteristics include degenerative changes in the collagenous matrix, hypercellularity, hypervascularity, and a lack of inflammatory cells, which has challenged the misnomer "tendinitis".
=== Hybrid scaffolds === A hybrid scaffold is a skin substitute based on a combination of synthetic and natural materials. Examples of hybrid scaffolds are HYAFF and Laserskin. These hybrid scaffolds have been shown to have good in-vitro and in-vivo biocompatibilities and their biodegradability is controllable.
Sources: en.wikipedia.org
== History == Romergoline was first described in the scientific literature in 1991. It was under development by Pharmacia Corporation, but its development was discontinued by the early 2000s and the drug was never marketed.
Bioequivalence is a term in pharmacokinetics used to assess the expected in vivo biological equivalence of two proprietary preparations of a drug. If two products are said to be bioequivalent it means that they would be expected to be, for all intents and purposes, the same. One article defined bioequivalence by stating that, "two pharmaceutical products are bioequivalent if they are pharmaceutically equivalent and their bioavailabilities (rate and extent of availability) after administration in the same molar dose are similar to such a degree that their effects, with respect to both efficacy and safety, can be expected to be essentially the same. Pharmaceutical equivalence implies the same amount of the same active substance(s), in the same dosage form, for the same route of administration and meeting the same or comparable standards." For The World Health Organization (WHO) "two pharmaceutical products are bioequivalent if they are pharmaceutically equivalent or pharmaceutical alternatives, and their bioavailabilities, in terms of rate (Cmax and tmax) and extent of absorption (area under the curve), after administration of the same molar dose under the same conditions, are similar to such a degree that their effects can be expected to be essentially the same".
=== Lactogenesis III === Prolactin and oxytocin are vital for establishing milk supply initially; however, once the milk supply is well established, the volume and content of the milk produced are controlled locally. Although prolactin levels are higher on average among breastfeeding mothers, prolactin levels themselves do not correlate to milk volume. At this stage, production of milk is triggered by milk drainage from the breasts. The only way to maintain milk supply is to drain the breasts frequently. Infrequent or incomplete drainage of the breasts, decreases blood flow to the alveoli and signals the milk-producing cells to produce less milk. Breast pumps are often used to drain the breasts when the infant is not feeding. A condition called Mastitis sometimes occurs in this stage, resulting from incomplete milk drainage. The Academy of Breastfeeding Medicine recommends against trying to "empty" the breasts, whether through pushing the baby to feed more or through over use of a breast pump, to prevent causing milk oversupply.
Smart TG, Stephenson FA (2019). "A half century of γ-aminobutyric acid". Brain Neurosci Adv. 3 2398212819858249. doi:10.1177/2398212819858249. PMC 7058221. PMID 32166183. Parviz M, Vogel K, Gibson KM, Pearl PL (2014-11-25). "Disorders of GABA metabolism: SSADH and GABA-transaminase deficiencies". Journal of Pediatric Epilepsy. 3 (4): 217–227. doi:10.3233/PEP-14097. PMC 4256671. PMID 25485164. Clinical disorders known to affect inherited GABA metabolism Gamma-aminobutyric acid MS Spectrum Scholarpedia article on GABA List of GABA neurons on NeuroLex.org Effects of Oral Gamma-Aminobutyric Acid (GABA) Administration on Stress and Sleep in Humans: A Systematic Review
All but two of Moore's cabinet nominees were unanimously confirmed by the Maryland Senate: Schiraldi, who faced opposition from Republicans over his policies toward juvenile justice reform; and Butler, whose critics claimed had not done enough to address complaints of racism and disparate treatment of Black officers in the Maryland State Police. Several of Moore's cabinet secretaries resigned in 2025. Kevin Anderson, the Maryland Secretary of Commerce, transitioned to an economic development advisor to the governor in January 2025 and was succeeded by Harry Coker, who served as the United States National Cyber Director from 2023 to 2025. Laura Herrera Scott resigned as Maryland Secretary of Health at the end of February 2025, and was succeeded by Meena Seshamani, who served as the director of the Centers for Medicare & Medicaid Services from 2021 to 2025. Anthony Woods resigned as Maryland Secretary of Veterans and Military Families to take a private sector job in May 2025, and was succeeded by Republican Carroll County commissioner Ed Rothstein in August 2025. In June 2025, Vincent Schiraldi resigned as Maryland Secretary of Juvenile Services, citing negative media attention of him and a small number of youth committing crimes, though Moore later claimed on WBAL-AM that he had "ordered" Schiraldi's resignation. In July 2025, Paul Wiedefeld said that he would resign as Maryland Secretary of Transportation on August 1; he was succeeded by Kathryn Thomas, who served as deputy administrator of the Federal Aviation Administration from 2023 to 2025.
Sources: en.wikipedia.org
The lyophilized powder is dissolved in a suitable solvent, often sterile water or a buffered diluent, with gentle mixing rather than vigorous shaking. Foaming and shear should be avoided because they can promote aggregation. The resulting solution is then stored cold and protected from light.
It usually represents the proportion of total chromatographic area attributable to the main peak. That figure does not account for impurities that do not absorb at the detection wavelength or that co-elute with the main peak. It is a useful but incomplete indicator of overall quality.
Yes. Immunoassays and chromatographic methods recognize different molecular features and can yield divergent results. Even within one technique, differences in columns, gradients, and reference standards shift reported values. Comparable numbers require a shared procedure and a common standard.
Native GLP-1 is degraded within minutes by dipeptidyl peptidase-4 and neutral endopeptidases. Semaglutide carries a non-natural amino acid at position eight that blocks that cleavage, and a fatty diacid side chain that binds albumin. The result is a much longer duration of action than the native hormone.